Results 231 to 240 of about 199,386 (303)

Another Microlesion Effect after STN‐DBS for Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Atsushi Umemura, Genko Oyama, Kenya Nishioka, Nobutaka Hattori   +3 more
wiley   +1 more source

Analyzing the ‘Bradykinesia Complex’ in Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Background Bradykinesia is the hallmark sign of parkinsonism. We recently proposed redefining bradykinesia as a complex of motor abnormalities, each reflecting separate pathophysiological elements. Objective To analyze the ‘bradykinesia complex’ in Parkinson's disease (PD) and healthy elderly individuals.
Giulia Paparella, Martina De Riggi, Antonio Cannavacciuolo, Daniele Birreci, Davide Costa, Luca Angelini, Danilo Alunni Fegatelli, Alfonso Fasano, Alberto J. Espay, Matteo Bologna   +9 more
wiley   +1 more source

MIF downregulation attenuates neuroinflammation via TLR4/MyD88/TRAF6/NF-κB pathway to protect dopaminergic neurons in Parkinson's disease model. [PDF]

Commun Biol
Huang Y, Zhou C, Qu S.
europepmc   +1 more source

The Second Hit Hypothesis in Animal and Human Dystonia: The Role of Peripheral Nerve Trauma and Spinal Cord Injury

Movement Disorders, EarlyView.
The “second‐hit” hypothesis proposes that both a genetic predisposition and an environmental insult—such as peripheral nerve trauma or spinal cord injury—are required for dystonia development. This review explores how neuroinflammation and maladaptive plasticity, triggered by nerve and spinal cord injury, contribute to dystonia pathogenesis.
Lisa Harder‐Rauschenberger, Chi Wang Ip   +1 more
wiley   +1 more source

Protocol for 3D direct reprogramming of human glia into dopaminergic neurons with gene expression and immunocytochemistry validation. [PDF]

STAR Protoc
Giacomoni J, Laurin K, Parmar M, Habekost M.   +3 more
europepmc   +1 more source

Altered Dopamine Metabolism and Response to Treatment with Levodopa/Carbidopa in MCT8 Deficiency

Movement Disorders, EarlyView.
Abstract Background Allan‐Herndon‐Dudley syndrome (AHDS)/monocarboxylate transporter 8 (MCT8) deficiency is a rare X‐linked encephalopathy caused by SLC16A2 variants, impairing thyroid hormone (TH) transport into the brain. This leads to early central nervous system (CNS) TH deficiency, affecting brain maturation.
Fabio Bruschi, Ylenia Vaia, Clara E. Antonello, Marco Spada, Francesco Porta, Cristina Marinaccio, Claudia Carducci, Thomas Opladen, Jacopo Sartorelli, Federica Maria Zibordi, Daniele Ghezzi, Francesco Nicita, Davide Tonduti   +12 more
wiley   +1 more source

Conditional Deletion of Translin/Trax in Dopaminergic Neurons Reveals No Impact on Psychostimulant Behaviors or Adiposity. [PDF]

Biomolecules
Liu Y, Wu R, Geng G, Yang H, Wang C, Ren M, Fu X.   +6 more
europepmc   +1 more source

Umbilical cord blood-derived exosomes attenuate dopaminergic neuron damage of Parkinson's disease mouse model [PDF]

Junjie Ye, Xiaodong Sun, Qi Jiang, Jianjun Gui, Shenglan Feng, Bingqing Qin, Lixia Xie, Ai Guo, Jinju Dong, Ming Sang   +9 more
openalex   +1 more source

LRRK2 as a Potential Disease‐Modifying Target in Sporadic Parkinson's Disease

Movement Disorders, EarlyView.
Abstract A growing understanding of the role that leucine‐rich repeat kinase 2 (LRRK2) plays in Parkinson's disease (PD) supports continued focus on this enzyme as a therapeutic target for PD. Accumulating evidence suggests that there are phenotypic, neuropathologic, and biological similarities between sporadic PD (sPD) and familial forms in which ...
Anthony E. Lang, Robert A. Hauser, Lorraine V. Kalia, Bonnie Hersh, Zdenek Berger, Roy Llorens Arenas, Coro Paisan‐Ruiz, Kyle Fraser, Danna Jennings, Jillian H. Kluss, Sarah Huntwork‐Rodriguez, Anastasia G. Henry, J. Timothy Greenamyre   +12 more
wiley   +1 more source